← All tickers

Is BCRX Worth Buying in 2026?

BioCryst Pharmaceuticals Inc

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-08-23

Here’s whether BioCryst Pharmaceuticals Inc (BCRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+3.06% over 10 days); RSI 59 — healthy momentum range; strong 1-year return of +14.0%; 3-month momentum positive (+15.2%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 14.9% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

BCRX is holding above its long-term 200-day MA ($8.43) but has slipped below the 50-day MA ($9.60), pointing to short-term weakness in an otherwise intact trend. An RSI of 59.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +14.0% compares to +20.5% for SPY (trailed the market by 6.5%).

$10,000 invested 1 year ago → $11,396 today
vs. S&P 500 (SPY) — same period trailed market by 6.5%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($8.43)
✗Above 50-day MA ($9.60)
✓RSI(14) neutral zone (30–70) — currently 59.3
✓Positive return (+14.0%)
!Within 10% of period high (−14.9%)
Period Range $9.55
$6.00 $11.22
RSI (14) 59.3
0 · OversoldOverbought · 100

Key Metrics

Price$9.55
Period Return+14.0%
Period High$11.22
Period Low$6.00
Drawdown−14.9%
MA-50$9.60
MA-200$8.43
RSI (14)59.3
Avg Volume (30d)3.3M
vs. SPYtrailed by 6.5%
Return Rank#451 of 999

Trade BCRX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers